EWM
LXRX icon

Executive Wealth Management’s Lexicon Pharmaceuticals LXRX Stock Holding History

Executive Wealth Management’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-1,100
Closed -$7K – 508
2019
Q2 		$7K Hold
1,100
– – ﹤0.01% 669
2019
Q1 		$6K Hold
1,100
– – ﹤0.01% 623
2018
Q4 		$7K Buy
+1,100
New +$8.91K ﹤0.01% 629

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
UL
Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Executive Wealth Management's LXRX Position: Q3 2019 in Review

Executive Wealth Management sold out of Lexicon Pharmaceuticals (LXRX) in Q3 2019, closing a stake of 1,100 shares — an estimated $7K sold.

Executive Wealth Management first reported a position in LXRX in Q4 2018 and held it in 3 quarters. The position peaked at $7K in Q2 2019. 103 funds tracked by Wall St. Rank hold LXRX as of Q3 2019.

  • Executive Wealth Management reported no remaining Lexicon Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • Executive Wealth Management sold 1,100 Lexicon Pharmaceuticals shares in Q3 2019, an estimated $7K.
  • Executive Wealth Management first reported a position in Lexicon Pharmaceuticals in Q4 2018 and held it in 3 quarters.
  • Executive Wealth Management's Lexicon Pharmaceuticals position peaked at $7K in Q2 2019.
  • 103 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q3 2019.

Based on Executive Wealth Management's 13F filing for Q3 2019, filed 30 Oct 2019.